JONATHAN MILNER

Jonathan Milner is a highly influential figure in the global biotechnology landscape, best known as the founder of Abcam plc, a company he grew into a FTSE 250 success story and a leading supplier of protein research tools worldwide. His career is marked by a profound commitment to scientific innovation and entrepreneurship, transitioning from a successful academic background to building and investing in groundbreaking life science ventures.

Milner's journey began with a PhD in Molecular Biology from the University of Bath, followed by postdoctoral research at the University of Cambridge. It was this deep scientific foundation that fueled his entrepreneurial spirit, leading him to establish Abcam in 1998. Under his leadership, first as CEO and later as Chairman, Abcam revolutionized the supply of antibodies and reagents, becoming an indispensable partner for researchers globally. His strategic vision and operational expertise were instrumental in scaling Abcam from a startup to a multi-billion-pound enterprise, demonstrating his capability to identify market needs and execute on a global scale.

Beyond Abcam, Jonathan Milner has cultivated a robust portfolio as an active angel investor and venture capitalist through his investment vehicle, Meltwind Advisory. His investment focus areas predominantly lie within the life sciences, biotechnology, diagnostics, and deep tech sectors. He is particularly drawn to early-stage companies with disruptive technologies and strong scientific foundations, aiming to support the next generation of innovators. Milner often takes on advisory or board roles, providing invaluable strategic guidance derived from his own entrepreneurial journey.

His notable investments reflect his commitment to advancing healthcare and scientific discovery. These include companies like PhoreMost, a drug discovery company leveraging novel protein degradation technologies; Horizon Discovery (acquired by PerkinElmer), a leader in gene editing and gene modulation tools; and Arecor Therapeutics, which focuses on developing superior biopharmaceuticals. Through these and many other investments, Milner continues to shape the future of biotech, fostering innovation and driving the commercialization of cutting-edge scientific research. His legacy extends beyond Abcam, positioning him as a pivotal force in the entrepreneurial ecosystem for life sciences.